Abstract Number: 1734 • ACR Convergence 2020
The Challenge of Assessing Wellbeing from the Patients` Perspective in Early Rheumatoid Arthritis
Background/Purpose: Although more effective therapeutics and treatment strategies for Rheumatoid Arthritis (RA) have improved many patient-reported outcomes (PROs), still a sizeable number of patients in…Abstract Number: 0141 • ACR Convergence 2020
Filgotinib Improved Work Productivity and Activity Impairment in Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results from FINCH-1 Study
Background/Purpose: Filgotinib (FIL) is a potent oral selective janus kinase 1 inhibitor which is currently being investigated as an agent to treat rheumatoid arthritis (RA).…Abstract Number: 0162 • ACR Convergence 2020
Identifying Sleep Problems in Systemic Juvenile Idiopathic Arthritis (SJIA) Patients with Patient-reported Outcomes (PRO) Questionnaires
Background/Purpose: Systemic Juvenile Idiopathic Arthritis (SJIA) can cause severe and chronic multisystem involvement. Medical therapies including high-dose corticosteroids can have significant side effects affecting sleep.…Abstract Number: 0347 • ACR Convergence 2020
In Two Phase-3 Trials, Guselkumab Reduced Fatigue over 52 Weeks in Patients with Psoriatic Arthritis and Demonstrated Independent Treatment Effects on Fatigue After Adjustment for Clinical Response (ACR20)
Background/Purpose: DISCOVER 1 & 2 are phase-3 trials of guselkumab (GUS, an IL-23 inhibitor) in patients with psoriatic arthritis (PsA). In both trials, treatment with…Abstract Number: 0814 • ACR Convergence 2020
“I Want to Switch Back”: Real-world Experience of Switching Intravenous Abatacept and Tocilizumab to Subcutaneous Injection During the COVID-19 Pandemic
Background/Purpose: During the COVID-19 pandemic, rapid guidelines by the National Institute for Health and Care Excellence (NICE) in the United Kingdom[1] recommended consideration of switching…Abstract Number: 1142 • ACR Convergence 2020
Implementation of an Evidence-based Transition Clinic in a Pediatric Rheumatology Academic Institution
Background/Purpose: Transition from pediatric to adult rheumatology care is more likely to be successful if a transition program is in place. Previously successful interventions to…Abstract Number: 1288 • ACR Convergence 2020
Predictors of Frailty Identified by the Short Physical Performance Battery and Associations with Patient-reported Outcomes
Background/Purpose: Frailty, defined as a generalized vulnerability to stressors, has emerged as a relevant concept in SLE1, although its origins are in geriatrics. As defined…Abstract Number: 1595 • ACR Convergence 2020
Using Rheumatoid Arthritis Communication Tool Developed by the RISE Learning Collaborative to Promote Shared Decision-Making
Background/Purpose: Patient care is moving from physician directed treatment to a co-design framework that focuses on creating a partnership between patients and physicians. This new…Abstract Number: 1738 • ACR Convergence 2020
Promote Treat-to-Target for RA via Empowering Patients: A Cohort Study from China by Smart System of Disease Management (SSDM)
Background/Purpose: Treat-to-Target (T2T) strategy are critical for the treatment of RA, but Chinese rheumatologists can hardly provide patients with a complete assessment in the clinic…Abstract Number: 0142 • ACR Convergence 2020
Filgotinib Improved Work Productivity and Activity Impairment in Patients with Rheumatoid Arthritis and Inadequate Response to Biologic DMARDs: Results from the FINCH 2 Study
Background/Purpose: Filgotinib (FIL) is a potent oral selective janus kinase 1 inhibitor which is currently being investigated as an agent to treat rheumatoid arthritis (RA).…Abstract Number: 0169 • ACR Convergence 2020
Patient-Reported Outcomes Differentiate Between Remission and Low Disease Activity in Psoriatic Arthritis
Background/Purpose: For psoriatic arthritis (PsA), several different composite instruments are available to define low disease activity (LDA) and remission (REM) targets for treatment. Patient-reported outcomes…Abstract Number: 0354 • ACR Convergence 2020
How Do TNF-alpha-Inhibitors in Medical History Affect Patient Reported Outcomes and Retention in Ankylosing Spondylitis Patients Treated with Secukinumab in Real World? – German Observational Study
Background/Purpose: Secukinumab (SEC), a fully human monoclonal antibody that selectively inhibits interleukin 17A, is approved for treatment of patients with ankylosing spondylitis (AS). However, there…Abstract Number: 0831 • ACR Convergence 2020
Sociodemographic, Disease, and Medication Profile of RA Patients Under 65 Years Compared with 65 Years or Older at Registry Enrollment: Real World Results from a Rheumatoid Arthritis Cohort
Background/Purpose: Age is an important factor that can affect disease course, physical function and treat to target strategy for patients with rheumatoid arthritis (RA). We…Abstract Number: 1145 • ACR Convergence 2020
Implementation of Web-Based Patient-Reported Outcome Measures (PROMs) in SLE Clinical Care: A Multi-Center Prospective Cohort Study
Background/Purpose: Patient-reported outcome measures (PROMs) are powerful tools which can highlight the patient experience of illness. Although PROMs are standard metrics in SLE clinical research,…Abstract Number: 1289 • ACR Convergence 2020
Sex Differences in Mental Health and Quality of Life and Their Impact in the Treatment of Patients with Systemic Lupus Erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE) predominantly affects young women. It is usually more aggressive in men and carries a worse prognosis. Information about gender differences…
ACR Meeting Abstracts